Daxor Corporation (DXR)

US — Healthcare Sector
Peers: INFU  MHUA  KRMD  LMAT    POCI  UTMD  MLSS  PDEX 

Automate Your Wheel Strategy on DXR

With Tiblio's Option Bot, you can configure your own wheel strategy including DXR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DXR
  • Rev/Share 0.1555
  • Book/Share 7.2539
  • PB 1.1843
  • Debt/Equity 0.0
  • CurrentRatio 0.0
  • ROIC 0.0

 

  • MktCap 41555033.0
  • FreeCF/Share -0.2829
  • PFCF -29.7664
  • PE 79.0377
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.0157

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
DXR
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

Daxor's Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant expansion of its blood volume analysis (BVA) capabilities in three new hospitals. This growth is accelerated by the widespread adoption of Daxor's ezBVA Lab service – a cutting-edge, CLIA-certified facility delivering precise, on-demand blood volume analysis results within 24 hours.

Read More
image for news Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
DXR
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung disease treatment for four days of innovative research and knowledge exchange.

Read More
image for news Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
DXR
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 04, 2025 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw.

Read More
image for news Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
DXR
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Leading Academic Health System Adopts Daxor's Innovative Blood Volume Measurement Capabilities at Two Key Facilities Oak Ridge, TN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) at two major hospitals within New Jersey's largest academic health care system. Based on current market momentum and expanding pipeline of opportunities, the Company expects to maintain this accelerated sales trajectory throughout 2025.

Read More
image for news Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
DXR
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge Oak Ridge, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces groundbreaking new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart Failure Therapeutics Conference (THT). Held from February 11-13, 2025, at the Omni Boston Hotel at the Seaport, the event gathered leading experts in heart failure innovation.

Read More
image for news Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
Daxor to Exhibit at World's Largest Critical Care Conference
DXR
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Daxor's Blood Volume Analysis (BVA) Technology Takes Center Stage at SCCM 2025 Oak Ridge, TN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress at the Orange County Convention Center in Orlando, FL from February 23 through February 25, 2025. The Company will be exhibiting at Booth #532.

Read More
image for news Daxor to Exhibit at World's Largest Critical Care Conference
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
DXR
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment Oak Ridge, TN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a groundbreaking case series published in JACC: Case Reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated red blood cells, opening new avenues for targeted treatment through therapeutic phlebotomy. In the study, researchers evaluated 179 advanced heart failure patients using Daxor's blood volume analysis …

Read More
image for news Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care
DXR
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor's Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.

Read More
image for news New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

About Daxor Corporation (DXR)

  • IPO Date 1983-07-25
  • Website https://www.daxor.com
  • Industry Medical - Instruments & Supplies
  • CEO Mr. Michael Richard Feldschuh
  • Employees 37

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.